Case Report: Successful management of psychogenic non-epileptic seizures with intranasal esketamine.
Frontiers in psychiatry – January 01, 2025
Source: PubMed
Summary
A groundbreaking case shows how intranasal esketamine helped a patient overcome both treatment-resistant depression and functional seizures. The medication completely stopped the patient's psychogenic seizures while significantly improving their anxiety and depression symptoms. This success suggests esketamine could offer new hope for people with complex neuropsychiatric disorders linked to past trauma.
Abstract
Psychogenic non-epileptic seizures (PNES), or functional seizures (FS), are episodes that resemble epileptic seizures but may be psychological in origin. Unlike epileptic seizures, which are linked to abnormal electrical activity in the brain, functional seizures may be associated with psychological and/or physical distress, and do not show the same electrical patterns on an electroencephalogram (EEG). Esketamine, a derivative of the anesthetic ketamine, is approved by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal thoughts or actions. This report discusses a patient with TRD and PNES, where the administration of esketamine effectively resolved both conditions. It explores the potential therapeutic effects of esketamine on PNES, in addition to its antidepressant properties.